EMA
safety_alert
· 2020-04-30
Risks of Picato for actinic keratosis outweigh benefits
Summary
The EMA states that the risks of Picato (ingenol mebate) for actinic keratosis outweigh the benefits and recommends restricting or withdrawing its use.
Upgrade for the full analysis, importance score, and drug timeline.